Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Připravované klinické studie
-
Zheng LiZatím nenabírámeKognitivní křehkost
-
Techpool Bio-Pharma Co., Ltd.Zatím nenabíráme
-
Istanbul University - CerrahpasaNáborDětská mozková obrnaTurecko (Türkiye)
-
Project Skin MDZatím nenabíráme
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Zatím nenabírámeAkutní ischemická cévní mozková příhoda AIS
-
Hospital Universitario La PazZatím nenabírámeNosní obstrukce | Bronchiolitida | Akutní infekce horních cest dýchacíchŠpanělsko
-
E-DA HospitalNational Cheng Kung University; Metal Industries Research & Development Centre...NáborObstrukční spánková apnoeTchaj-wan
-
Assistance Publique - Hôpitaux de ParisZatím nenabírámeKomplikace extrakorporální membránové okysličení | ECMO Cannula InfectionFrancie
-
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.NáborRakovina prsu | Rakovina žaludku | Rakovina vaječníků | Pokročilé pevné nádory | Jiné solidní nádoryČína
-
Gustave Roussy, Cancer Campus, Grand ParisZatím nenabírámeAdult Carriers of a Pathogenic or Probably Pathogenic (Class 4 and 5) Germline Variation in the TP53 GeneFrancie
-
Assistance Publique - Hôpitaux de ParisNábor
-
University GhentZatím nenabírámePooperační bolest, akutní | Ireverzibilní pulpitida (bolest zubů) | Pulp Necrosis, Apical PeriodontitisBelgie
Clinical Research Jobs
-
Italy - Milan
-
United States - Shrewsbury
-
United Kingdom - Leeds
-
India - Kochi
-
United States - Massachusetts - Boston
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China